Journal article
Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis
Abstract
BACKGROUND: Chronic kidney disease-mineral and bone disorders (CKD-MBD) have been associated with poor health outcomes, including diminished quality and length of life. Standard management for CKD-MBD includes phosphate restricted diet, vitamin D and phosphate binders. Persistently elevated parathyroid hormone levels may require the addition of cinacalcet hydrochloride (cinacalcet), which sensitizes calcium receptors in the parathyroid gland.
Authors
Sekercioglu N; Busse JW; Sekercioglu MF; Agarwal A; Shaikh S; Lopes LC; Mustafa RA; Guyatt GH; Thabane L
Journal
Renal Failure, Vol. 38, No. 6, pp. 857–874
Publisher
Taylor & Francis
Publication Date
July 2, 2016
DOI
10.3109/0886022x.2016.1172468
ISSN
0886-022X